US Drug Recall Register

FDA Drug Recalls

17,898 recalls, newest first

Class III · Low risk Terminated

Acyclovir Tablets

Reason Labeling: Incorrect or Missing Lot and/or Exp Date

Heritage Pharmaceuticals Inc NDC 23155-227-01 D-0367-2021
Class I · High risk Terminated

BD ChloraPrep Hi-Lite Orange 26 mL Applicator

Reason Defective Delivery System: An increase in complaints identified endcap being loose or falling off upon activation releasing glass shards containing the solution.

CareFusion 213, LLC NDC 54365-400-38 D-0373-2021
Class III · Low risk Terminated

Evrysdi

Reason Defective Container: complaints received regarding some incorrect press-in-bottle-adapters (PIBA), the incorrect PIBAs have a female instead of male fit so they cannot be used in combination with co-packed syringes.

Genentech Inc D-0357-2021
Class III · Low risk Terminated

Asenapine Sublingual Tablets

Reason Incorrect Product Formulation; product was manufactured with the incorrect Art Cherry Flavor flavoring agent instead of Art Black Cherry Flavor flavoring agent

SigmaPharm Laboratories LLC NDC 42794-017-10 D-0380-2021
Class III · Low risk Terminated

Asenapine Sublingual Tablets

Reason Incorrect Product Formulation; product was manufactured with the incorrect Art Cherry Flavor flavoring agent instead of Art Black Cherry Flavor flavoring agent

SigmaPharm Laboratories LLC NDC 42794-016-10 D-0379-2021
Class II · Moderate risk Terminated

Estradiol Transdermal System Delivers 0.0375 mg/day

Reason Defective Delivery System: Out of specification for release rate testing and shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not stick well to the skin.

Noven Pharmaceuticals Inc NDC 68968-3437-8 D-0337-2021
Class II · Moderate risk Terminated

Minivelle

Reason Defective Delivery System: Out of specification for release rate testing and shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not stick well to the skin.

Noven Pharmaceuticals Inc NDC 68968-6675-8 D-0336-2021
Class II · Moderate risk Terminated

Oxygen

Reason cGMP deviations

Grace Healthcare Medical, Inc D-0355-2021
Class III · Low risk Terminated

Dry Eye Test

Reason Subpotent Drug

Nomax Inc D-0387-2021
Class II · Moderate risk Ongoing

Cephalexin for Oral Suspension

Reason Failed Impurities/degradation specifications: Repackager recall due to Out of Specification detected by manufacturer for Individual Unidentified Impurity found during related substance test analysis of Cephalexin

Preferred Pharmaceuticals, Inc. D-0342-2021
Class II · Moderate risk Terminated

Betadine

Reason Defective container; syringe content migrating past the seal of the plunger may cause a lack of assurance of sterility

Edge Pharma, LLC D-0335-2021
Class II · Moderate risk Ongoing

Flurandrenolide Ointment USP

Reason Failed Impurities/Degradation Specifications:

Teligent Pharma, Inc. NDC 52565-017-60 D-0356-2021
Class I · High risk Ongoing

Ginseng Power 5000 capsule

Reason Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and/ or tadalafil

NSNY Distributor Inc D-0642-2021
Class I · High risk Ongoing

Premium OrgaZEN 7000 capsule

Reason Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and/ or tadalafil

NSNY Distributor Inc D-0641-2021
Class II · Moderate risk Ongoing

Triple SupremeZen Plus 3500

Reason Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil.

Hyobin LLC D-0383-2021
Class II · Moderate risk Ongoing

PremierZen Black 5000

Reason Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil.

Hyobin LLC D-0382-2021
Class II · Moderate risk Ongoing

PremierZen Extreme 3000

Reason Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil.

Hyobin LLC D-0381-2021
Class II · Moderate risk Terminated

Itraconazole Capsules

Reason Failed Dissolution Specifications

Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-282-30 D-0333-2021
Class II · Moderate risk Ongoing

Imperial Platinum 2000

Reason Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil and/or sildenafil.

QMart D-0371-2021
Class II · Moderate risk Ongoing

Burro en Primavera

Reason Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil and/or sildenafil.

QMart D-0370-2021
Class II · Moderate risk Ongoing

PremierZen Extreme 3000

Reason Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil and/or sildenafil.

QMart D-0369-2021
Class II · Moderate risk Ongoing

Imperial Gold 2000

Reason Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil and/or sildenafil.

QMart D-0368-2021
Class II · Moderate risk Terminated

Riomet

Reason Microbial Contamination of Non-Sterile Product

Sun Pharmaceutical Industries INC NDC 10631-206-02 D-0334-2021
Class II · Moderate risk Ongoing

Guanfacine Extended-Release Tablets 2 mg

Reason Cross Contamination with Other Product: Product is being recalled due to Trace Amounts of Quetiapine Fumarate

Apotex Corp. NDC 60505-3928-1 D-0324-2021